Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 107 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fluticasone propionate/salmeterol Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Advair HFA in Healthy and HAPE Predisposed Subjects

NCT06040268
View directory record Official record
Conditions
Altitude Edema
Interventions
Advair HFA, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 12, 2026, 8:33 AM EDT
Completed No phase listed Observational

Replication of the INSPIRE Trial in Healthcare Claims Data

NCT05179512
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Tiotropium, salmeterol-fluticasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
98,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Completed No phase listed Observational Results available

Pharmacogenetics of b2-Agonists in Asthma.

NCT00708227
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 4 Interventional Results available

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

NCT01124422
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

NCT00461812
View directory record Official record
Conditions
Asthma
Interventions
Mometasone, Advair
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Not listed Phase 4 Interventional

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

NCT00867737
View directory record Official record
Conditions
Asthma
Interventions
Advair HFA MDI 115/21, Symbicort 160/4.5 pMDI
Drug
Lead sponsor
Allergy and Asthma Center of El Paso
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 4 Interventional

GSK BHR Study (Sont)

NCT00920543
View directory record Official record
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 500mcg, FP 250mcg, FSC 100/50mcg, FSC 250/50mcg, FSC 500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 4 Interventional Results available

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

NCT00633217
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Not applicable Interventional Results available

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

NCT01117116
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate and salmeterol, budesonide and formoterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 4 Interventional Results available

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

NCT01462344
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR 100/50mcg, ADVAIR 250/50mcg, FLOVENT 100mcg, FLOVENT 250mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
267
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 4 Interventional Results available

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

NCT00118716
View directory record Official record
Conditions
Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions
Fluticasone propionate/salmeterol, Fluticasone Propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 17 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
50
States / cities
Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

NCT03207243
View directory record Official record
Conditions
Asthma
Interventions
GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 4 Interventional

GSK BHR Study (Sont - Second Study)

NCT01324362
View directory record Official record
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 4 Interventional Results available

The Effect on Depressive Symptoms in ECF Residents With COPD

NCT00974246
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Depression
Interventions
Advair diskus
Drug
Lead sponsor
Valley Medical Research
Other
Eligibility
18 Years to 94 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Brooksville, Florida • Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

NCT00116402
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone and salmeterol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00268216
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50mcg/ Fluticasone Propionate 500mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
6,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
190
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

NCT03535870
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Not applicable Interventional Results available

The Effect of Salmeterol on Eosinophil (EOS) Function

NCT00214019
View directory record Official record
Conditions
Allergic Asthma
Interventions
salmeterol, Fluticasone, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Early Phase 1 Interventional

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

NCT02826343
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 12, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00669617
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 12, 2026, 8:33 AM EDT